UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Visuospatial planning in unmedicated major depressive and bipolar disorder: distinct and common neural correlates

European neuropsychopharmacology, 2016-10, Vol.26, p.S374-S375

2016

Volltextzugriff (PDF)

P.2.f.015 Omega-3 polyunsaturated fatty acids for major depressive disorder: an updated meta-analysis of randomised clinical trials

European neuropsychopharmacology, 2015-09, Vol.25, p.S442-S443

2015

Volltextzugriff (PDF)

Season and gender modify in-vivo serotonin transporter binding in depressed patients and healthy controls

Journal of affective disorders, 2008, Vol.107, p.S78-S78

2008

Volltextzugriff (PDF)

Investigating serotonergic function using positron emission tomography: overview and recent findings

Current pharmaceutical design, 2010-06, Vol.16 (18), p.1979-1989

2010

Volltextzugriff (PDF)

DHEAS and cortisol/DHEAS-ratio in recurrent depression: State, or trait predicting 10-year recurrence?

Psychoneuroendocrinology, 2015-09, Vol.59, p.91-101

2015

Volltextzugriff (PDF)

P.2.c.030 Volumetric changes in amygdala and hippocampus after three months of paroxetine treatment for major depressive disorder

European neuropsychopharmacology, 2012-10, Vol.22, p.S267-S268

2012

Volltextzugriff (PDF)

S.13.04 fMRI markers for the prediction of short- and long-term outcome in major depressive disorder

European neuropsychopharmacology, 2014-10, Vol.24, p.S130-S130

2014

Volltextzugriff (PDF)

Decrease of amygdala-hyperactivation in MDD is associated with paroxetine SERT-occupancy

Journal of affective disorders, 2010-04, Vol.122, p.S66-S67

2010

Volltextzugriff (PDF)

Six weeks of paroxetine treatment improves dorsolateral prefrontal brain activity. An fMRI study using the Tower of London

Journal of affective disorders, 2010-04, Vol.122, p.S67-S68

2010

Volltextzugriff (PDF)

Randomized dose escalation of paroxetine in depressed patients visualized by [123 I]β-CIT SPECT

Journal of affective disorders, 2008, Vol.107, p.S77-S77

2008

Volltextzugriff (PDF)

The effect of paroxetine on amygdala reactivity after emotional faces measured with fMRI

Journal of affective disorders, 2008, Vol.107, p.S78-S78

2008

Volltextzugriff (PDF)

P.2.c.022 Twelve weeks of paroxetine treatment improves prefrontal brain activity. An fMRI study using the Tower of London

European neuropsychopharmacology, 2010, Vol.20, p.S380-S380

2010

Volltextzugriff (PDF)

Biological profiling of prospective antidepressant response in major depressive disorder: Associations with (neuro)inflammation, fatty acid metabolism, and amygdala-reactivity

Psychoneuroendocrinology, 2017-05, Vol.79, p.84-92

2017

Volltextzugriff (PDF)

P.2.c.039 Noradrenergic uptake inhibition of higher doses of paroxetine in relation to clinical efficacy: the DELPHI-study

European neuropsychopharmacology, 2010, Vol.20, p.S390-S391

2010

Volltextzugriff (PDF)

P.1.29 The decrease of amygdala hyperactivation in depression is associated with paroxetine serotonin transporter occupancy

European neuropsychopharmacology, 2009, Vol.19, p.S25-S26

2009

Volltextzugriff (PDF)

Serotonin transporter (SERT) polymorphism modifies the association between SERT occupancy and paroxetine treatment response: A [123 I]β-CIT SPECT study

Journal of affective disorders, 2008, Vol.107, p.S63-S64

2008

Volltextzugriff (PDF)

Prediction of response to paroxetine treatment in patients with a depressive disorder

Journal of affective disorders, 2008, Vol.107, p.S87-S87

2008

Volltextzugriff (PDF)

Decreased functional connectivity of the insula within the salience network as an indicator for prospective insufficient response to antidepressants

NeuroImage clinical, 2019-01, Vol.24, p.102064-102064, Article 102064

2019

Volltextzugriff (PDF)

P.2.c.015 The effect of paroxetine on amygdala reactivity after emotional faces measured with fMRI

European neuropsychopharmacology, 2008, Vol.18, p.S332-S333

2008

Volltextzugriff (PDF)

P.2.h.002 Medication discrepancies in outpatients with mood and anxiety disorders. Risks and clinical relevance

European neuropsychopharmacology, 2015-09, Vol.25, p.S454-S454

2015

Volltextzugriff (PDF)

P.2.a.009 - Visuospatial planning in unmedicated major depressive and bipolar disorder: distinct and common neural correlates

European neuropsychopharmacology, 2016-10, Vol.26, p.S374-S375

2016

Volltextzugriff (PDF)

Attenuated resting-state default mode network connectivity in remitted depression after sad autobiographical recall

European neuropsychopharmacology, 2016-10, Vol.26, p.S137-S137

2016

Volltextzugriff (PDF)

S.09.02 Neuropsychological and neuroimaging markers for recurrence of major depressive disorder

European neuropsychopharmacology, 2019, Vol.29, p.S12-S13

2019

Volltextzugriff (PDF)

Persisting neuropsychological cognitive-affective deficits in emotional processing during remission in recurrent major depressive disorder: associations with cognitive reactivity and future recurrence?

European neuropsychopharmacology, 2016-10, Vol.26, p.S345-S345

2016

Volltextzugriff (PDF)

P.1.g.047 Biological profiling of antidepressant response in depression: associations with neuroinflammation, fatty acid metabolism, and amygdala-reactivity

European neuropsychopharmacology, 2015-09, Vol.25, p.S262-S263

2015

Volltextzugriff (PDF)

1 – 25 von 50

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(44)
Mit Volltextzugriff
(46)

Publikationsform

Artikel
(49)
Buchkapitel
(1)

Sprache

Englisch
(49)
Niederländisch
(1)

Erscheinungsjahr

n.n

Thema

Psychiatry
(33)
Internal Medicine
(17)
Humans
(12)
Life Sciences & Biomedicine
(12)
Science & Technology
(12)
Female
(8)
Male
(8)
Middle Aged
(8)
Neurosciences & Neurology
(8)
Adult
(7)
Major Depressive Disorder
(6)
Clinical Neurology
(4)
Neurosciences
(4)
Case-Control Studies
(3)
Endocrinology & Metabolism
(3)
Treatment Outcome
(3)
Aged
(2)
Antidepressive Agents - Therapeutic Use
(2)
Brain - Pathology
(2)
Cortisol
(2)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Visuospatial planning in unmedicated major depressive and bipolar disorder: distinct and common neural correlates

P.2.f.015 Omega-3 polyunsaturated fatty acids for major depressive disorder: an updated meta-analysis of randomised clinical trials

Season and gender modify in-vivo serotonin transporter binding in depressed patients and healthy controls

Investigating serotonergic function using positron emission tomography: overview and recent findings

DHEAS and cortisol/DHEAS-ratio in recurrent depression: State, or trait predicting 10-year recurrence?

P.2.c.030 Volumetric changes in amygdala and hippocampus after three months of paroxetine treatment for major depressive disorder

S.13.04 fMRI markers for the prediction of short- and long-term outcome in major depressive disorder

Decrease of amygdala-hyperactivation in MDD is associated with paroxetine SERT-occupancy

Six weeks of paroxetine treatment improves dorsolateral prefrontal brain activity. An fMRI study using the Tower of London

Randomized dose escalation of paroxetine in depressed patients visualized by [123 I]β-CIT SPECT

The effect of paroxetine on amygdala reactivity after emotional faces measured with fMRI

P.2.c.022 Twelve weeks of paroxetine treatment improves prefrontal brain activity. An fMRI study using the Tower of London

Biological profiling of prospective antidepressant response in major depressive disorder: Associations with (neuro)inflammation, fatty acid metabolism, and amygdala-reactivity

P.2.c.039 Noradrenergic uptake inhibition of higher doses of paroxetine in relation to clinical efficacy: the DELPHI-study

P.1.29 The decrease of amygdala hyperactivation in depression is associated with paroxetine serotonin transporter occupancy

Serotonin transporter (SERT) polymorphism modifies the association between SERT occupancy and paroxetine treatment response: A [123 I]β-CIT SPECT study

Prediction of response to paroxetine treatment in patients with a depressive disorder

Decreased functional connectivity of the insula within the salience network as an indicator for prospective insufficient response to antidepressants

P.2.c.015 The effect of paroxetine on amygdala reactivity after emotional faces measured with fMRI

P.2.h.002 Medication discrepancies in outpatients with mood and anxiety disorders. Risks and clinical relevance

P.2.a.009 - Visuospatial planning in unmedicated major depressive and bipolar disorder: distinct and common neural correlates

Attenuated resting-state default mode network connectivity in remitted depression after sad autobiographical recall

S.09.02 Neuropsychological and neuroimaging markers for recurrence of major depressive disorder

Persisting neuropsychological cognitive-affective deficits in emotional processing during remission in recurrent major depressive disorder: associations with cognitive reactivity and future recurrence?

P.1.g.047 Biological profiling of antidepressant response in depression: associations with neuroinflammation, fatty acid metabolism, and amygdala-reactivity

Suchergebnisse filtern